Glial and neuronal dysfunction in streptozotocin-induced diabetic rats

Abstract

Neuronal dysfunction has been noted very soon after the induction of diabetes by streptozotocin injection in rats. It is not clear from anatomical evidence whether glial cell dysfunction accompanies the well-documented neuronal deficit. Here, we isolate the Müller cell driven slow-P3 component of the full-field electroretinogram and show that it is attenuated at 4 weeks following the onset of streptozotocin-hyperglycaemia. We also found a concurrent reduction in the sensitivity of the phototransduction cascade, as well as in the components of the electroretinogram known to indicate retinal ganglion cell and amacrine cell integrity. Our data support the idea that neuronal and Müller cell dysfunction occurs at the same time in streptozotocin-induced hyperglycaemia.

Regenerative Therapeutic Potential of Adipose Stromal Cells in Early Stage Diabetic Retinopathy

“…Similarly, here we demonstrate significant changes in ‘b’ wave amplitudes represented by bipolar and Muller cells in our diabetic rats within two months of diabetes. These early ERG changes are in support of the idea that neuronal and Müller cell dysfunction occurs at the same time in streptozotocin-induced hyperglycemia[53]. Although we were unable to trace oscillatory potentials, which were highly correlated with DR progression [54], our data with intravitreal injection of ASC demonstrating the restoration of near normal ‘b’ wave amplitudes suggested a beneficial role for ASC in DR.…”

Susceptibility of Streptozotocin-Induced Diabetic Rat Retinal Function and Ocular Blood Flow to Acute Intraocular Pressure Challenge

“…The key finding of this study was that as early as 4 weeks following the onset of chronic hyperglycemia, before changes in the major components of the ERG, 18,[41][42][43] retinal function (Fig. 3) shows greater susceptibility to acute IOP challenge.…”

Retinal Electrophysiology Is a Viable Preclinical Biomarker for Drug Penetrance into the Central Nervous System

“…Drugs were introduced into the vitreous to bypass the blood-retina barrier. As previously described [ 47 ], a 30 G needle was connected via a length of polyethylene tubing (inner diameter 0.38 mm, Portex Limited, Kent, UK) to a Hamilton syringe (SGE® Analytical Sciences Pty Ltd., Ringwood, VIC, Australia). The needle was inserted into the vitreal chamber 2 mm behind the limbus at a 45° angle to a depth of 2.5 mm.…”